CTXR Citius Pharmaceuticals, Inc.

Nasdaq citiuspharma.com


$ 1.47 $ -0.03 (-2.03 %)    

Friday, 17-Oct-2025 18:02:57 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.45
$ 1.47
$ 1.31 x 2,001
$ 1.53 x 300
$ 1.33 - $ 1.48
$ 0.65 - $ 12.84
1,119,763
na
nm
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 12-27-2024 09-30-2024 10-K
5 08-12-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 12-29-2023 09-30-2023 10-K
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-Q
12 12-22-2022 09-30-2022 10-K
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 02-10-2022 12-31-2021 10-Q
16 12-15-2021 09-30-2021 10-K
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 02-11-2021 12-31-2020 10-Q
20 12-16-2020 09-30-2020 10-K
21 08-14-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 02-13-2020 12-31-2019 10-Q
24 12-16-2019 09-30-2019 10-K
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-Q
28 12-11-2018 09-30-2018 10-K
29 08-14-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 02-14-2018 12-31-2017 10-Q
32 12-13-2017 09-30-2017 10-K
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 02-14-2017 12-31-2016 10-Q
36 12-23-2016 09-30-2016 10-K
37 08-15-2016 06-30-2016 10-Q
38 05-20-2016 03-31-2016 10-Q
39 02-12-2016 12-31-2015 10-Q
40 12-14-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutan...

Core News & Articles

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc...

Core News & Articles

Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targe...

 d-boral-capital-maintains-buy-on-citius-pharmaceuticals-maintains-6-price-target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.

 citius-pharma-q3-eps-080-misses-058-estimate

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.5...

Core News & Articles

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius...

Core News & Articles

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for ...

 d-boral-capital-maintains-buy-on-citius-pharmaceuticals-maintains-6-price-target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.

 citius-pharmaceuticals-stock-is-falling-tuesday-whats-going-on

Citius announced a $15.8 million direct offering.

 d-boral-capital-maintains-buy-on-citius-pharmaceuticals-lowers-price-target-to-6

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and lowers the price target...

 citius-pharma-secures-122share-direct-offering-selling-492m-shares--warrants

$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of sho...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION